The Lancet Respiratory Medicine in conversation with
Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COVID outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
The Lancet Respiratory Medicine in conversation with
Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis
Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.
Read the full article:
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv